Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors
Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors
- Disease:Anaplastic large cell lymphoma T- and null-cell typesInflammatory myofibroblastic tumour
- Substances:Brigatinib
Spain- Participants:0–17 years · 18–64 years
- Substances:Brigatinib
- Sponsor:Princess Maxima Center For Pediatric Oncology









